Jaundice Treatment: Complete 2026 US Doctor’s Guide (NIDDK + AASLD + FDA)

Short answer: Jaundice treatment is cause-specific. For pre-hepatic (haemolysis): treat the underlying anaemia (steroids, splenectomy, transfusion, hydroxyurea for sickle cell). For hepatic: cure hepatitis C with direct-acting antivirals in 8–12 weeks (sofosbuvir-velpatasvir, glecaprevir-pibrentasvir); suppress hepatitis B with tenofovir or entecavir; stop toxins including alcohol and offending drugs; treat MASLD with weight loss, GLP-1s (Zepbound, Wegovy) and the first FDA-approved resmetirom (Rezdiffra) for MASH 2024; treat autoimmune hepatitis with corticosteroids; PBC with ursodeoxycholic acid (UDCA) and obeticholic acid. For post-hepatic: ERCP with stone extraction, biliary stenting, or surgery. Severe liver failure may need liver transplantation. Neonatal jaundice is treated with phototherapy and rarely exchange transfusion.

Table of Contents

1. Principle — Treat the Cause
2. Treating Pre-Hepatic Causes
3. Treating Viral Hepatitis
4. Treating Alcohol-Associated Liver Disease
5. Treating MASLD / MASH
6. Autoimmune and Cholestatic Diseases
7. Drug-Induced Liver Injury
8. Treating Obstructive Jaundice
9. Neonatal Jaundice Treatment
10. Liver Transplantation
11. Supportive Care and Monitoring
12. FAQs
13. References

1. Principle — Treat the Cause

Jaundice is a sign, not a disease. US AASLD and NIDDK guidance stresses rapid work-up (LFTs, fractionated bilirubin, viral serologies, ultrasound, MRCP) to identify the cause, then target it directly. Early, accurate treatment usually reverses jaundice and prevents complications.

2. Treating Pre-Hepatic Causes

• Autoimmune haemolytic anaemia: corticosteroids, rituximab, IVIG, splenectomy for refractory cases
• Hereditary spherocytosis: folic acid, splenectomy
• G6PD deficiency: avoid triggers (fava beans, dapsone, sulfa drugs, naphthalene)
• Sickle cell disease: hydroxyurea, L-glutamine, voxelotor, crizanlizumab, transfusion exchange; FDA-approved gene therapies (Casgevy, Lyfgenia) 2023
• Thalassaemia: transfusion + chelation; luspatercept
• Gilbert syndrome: no treatment needed; reassurance

3. Treating Viral Hepatitis

• Hepatitis A: supportive; vaccine for prevention and post-exposure prophylaxis
• Hepatitis B: nucleos(t)ide analogues — tenofovir (TDF, TAF) or entecavir; peg-interferon in selected cases; monitor viral load, LFTs, HCC screening (US & AFP)
• Hepatitis C: direct-acting antivirals (DAAs) cure >95% in 8–12 weeks — sofosbuvir-velpatasvir (Epclusa), glecaprevir-pibrentasvir (Mavyret); universal US adult screening per CDC
• Hepatitis D: peg-interferon alfa; bulevirtide (Hepcludex) approved in EU, not yet FDA; emerging treatments
• Hepatitis E: supportive; ribavirin for chronic HEV in immunocompromised

4. Treating Alcohol-Associated Liver Disease

• Complete abstinence — foundational
• Nutritional support — thiamine, folate, zinc, protein
• Alcoholic hepatitis (severe): prednisolone 40 mg/day for 28 days if MDF ≥32 or MELD ≥20 (Lille score reassessment at day 7); pentoxifylline no longer recommended
• Treat AUD: naltrexone, acamprosate, disulfiram, bariatric adjuncts, CBT, SAMHSA 1-800-662-HELP
• Vaccinate against HAV, HBV, flu, COVID, pneumococcus
• Monitor for cirrhosis complications
• Early liver transplant evaluation for severe alcoholic hepatitis in selected US centres

5. Treating MASLD / MASH

• 7–10% body weight loss reverses fatty liver and MASH
• Mediterranean / DASH diet; eliminate added sugars; reduce ultra-processed foods
• Exercise 150 min/week + resistance training
• Treat metabolic syndrome: statin for dyslipidaemia, blood-pressure control, HbA1c ≤7%
• GLP-1 / GIP receptor agonists: semaglutide (Wegovy), tirzepatide (Zepbound) reduce liver fat and NASH
• Resmetirom (Rezdiffra) — first FDA-approved MASH drug, March 2024; thyroid hormone receptor-β agonist
• Vitamin E 800 IU/day in biopsy-proven NASH without diabetes (AASLD 2024)
• Avoid alcohol

6. Autoimmune and Cholestatic Diseases

• Autoimmune hepatitis (AIH): prednisolone + azathioprine → mycophenolate as alternative; lifelong monitoring; AASLD 2024 guideline
• Primary biliary cholangitis (PBC): first-line ursodeoxycholic acid (UDCA); add obeticholic acid (Ocaliva), fibrates, or elafibranor (Iqirvo) FDA-approved 2024, seladelpar (Livdelzi) FDA 2024 for inadequate UDCA responders
• Primary sclerosing cholangitis (PSC): ERCP for strictures; no proven disease-modifying drug yet; transplant for advanced disease
• Pruritus: cholestyramine, rifampin, naltrexone, sertraline, UV light

7. Drug-Induced Liver Injury (DILI)

• Stop the offending drug immediately
• Acetaminophen overdose — N-acetylcysteine (NAC) within 8 h; Rumack-Matthew nomogram
• Supportive care; liver transplant for acute liver failure
• Report via FDA MedWatch
• Avoid herbal/dietary supplements of unclear safety

8. Treating Obstructive Jaundice

• Choledocholithiasis: ERCP with sphincterotomy and stone extraction; cholecystectomy for gallstones
• Cholangitis: broad-spectrum IV antibiotics (piperacillin-tazobactam, meropenem), fluid resuscitation, urgent ERCP drainage
• Pancreatic cancer: biliary stent via ERCP for palliation; Whipple surgery for resectable disease; chemotherapy (FOLFIRINOX, gemcitabine-nab-paclitaxel)
• Cholangiocarcinoma: biliary stent, surgical resection, chemotherapy, immunotherapy (durvalumab + gemcitabine-cisplatin FDA 2022)
• Benign strictures: endoscopic dilation + stenting

9. Neonatal Jaundice Treatment

• Phototherapy with specific blue light wavelengths — converts bilirubin to water-soluble isomers
• Based on hour-of-life bilirubin nomogram (AAP 2022 updated thresholds)
• Encourage breastfeeding; adequate hydration
• Exchange transfusion in extreme hyperbilirubinaemia
• IVIG for isoimmune haemolytic disease
• Early referral to pediatric gastroenterology for suspected biliary atresia — Kasai hepatoportoenterostomy by 8 weeks

10. Liver Transplantation

US has an advanced transplant network (UNOS/OPTN). Indications:

• Acute liver failure (acetaminophen, acute hepatitis B, autoimmune)
• Decompensated cirrhosis (MELD score ≥15)
• Hepatocellular carcinoma within Milan criteria
• Severe alcoholic hepatitis (selected centres)
• PBC/PSC with intractable complications

>9,500 liver transplants/year in the US; 5-year survival ~75–80%. Both deceased and living donor options.

11. Supportive Care and Monitoring

• Hydration, nutrition
• Monitor LFTs, INR, albumin, bilirubin trend
• Pruritus relief as above
• Vaccinate against hepatitis A and B if susceptible
• Avoid alcohol and hepatotoxic drugs (over-the-counter supplements included)
• Low-sodium diet in cirrhosis with ascites
• Lactulose + rifaximin for encephalopathy
• HCC surveillance every 6 months in cirrhosis (U/S ± AFP)

Related reading: Jaundice causes, jaundice symptoms, what to eat for jaundice, and what 7 foods are good for your liver.

12. External Video Resource

NIDDK + AASLD: Jaundice and Liver Disease Treatments (YouTube)

13. FAQs

Q1. Can jaundice be fully cured?
Yes — most causes can be cured or substantially controlled with appropriate US treatment.

Q2. How quickly does hepatitis C treatment work?
8–12 weeks of DAAs cure >95%.

Q3. Does Rezdiffra really work for fatty liver?
FDA approved March 2024 for MASH with moderate-advanced fibrosis — reduced NASH and fibrosis in Phase 3 (MAESTRO-NASH).

Q4. How is a bile-duct stone removed?
ERCP with sphincterotomy and basket/balloon extraction.

Q5. Can liver transplant cure cirrhosis?
Yes — for selected patients meeting MELD/criteria at a US transplant center.

Q6. Is alcoholic hepatitis treatment different for women?
Women develop ALD at lower alcohol doses but the same drugs apply.

Q7. Can I take vitamin supplements for liver?
Only vitamin E in biopsy-proven NASH per AASLD; avoid high-dose supplements without physician guidance — many cause DILI.

14. US Resources

• NIDDK, AASLD, American Liver Foundation
• CDC Hepatitis Testing Day
• SAMHSA 1-800-662-HELP for alcohol-related jaundice
• UNOS/OPTN for transplant information

15. Conclusion

Jaundice treatment is cause-specific and increasingly effective. US patients benefit from HCV cures with DAAs, HBV suppression, Rezdiffra for MASH, UDCA/obeticholic/elafibranor/seladelpar for PBC, ERCP, and a world-leading transplant network. See a US clinician promptly for any jaundice.

16. References

1. AASLD. Practice Guidelines (HCV, HBV, PBC, MASH, AIH), 2024.
2. FDA. Approval of Rezdiffra for MASH, March 2024.
3. FDA. Approval of Elafibranor (Iqirvo) and Seladelpar (Livdelzi) for PBC, 2024.
4. NIDDK. Jaundice Treatment Overview, 2024.
5. AAP. Hyperbilirubinemia Clinical Practice Guideline, 2022.
6. UNOS. US Liver Transplant Statistics, 2024.

Medical Disclaimer: This article is for educational and informational purposes only and does not substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider regarding any medical condition or before making any decisions related to your health. Do not disregard or delay seeking professional advice based on information provided in this article.